Abstract
Pharmacologic thromboprophylaxis with low-molecular-weight heparins, vitamin K antagonists, or fondaparinux is well tolerated and effective in preventing venous thromboembolism (VTE) in major orthopedic surgery but is often limited to in-hospital use. However, 45% to 80% of all symptomatic VTE events occur after hospital discharge. Extended-duration VTE prophylaxis for 28 to 35 days reduces risk for late VTE by up to 70%. In this article, I review the evidence supporting guideline recommendations regarding extended-duration prophylaxis after major orthopedic surgery and provide an overview of current and emerging literature regarding prevention of postoperative VTE in patients undergoing this surgery.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 394-401 |
| Number of pages | 8 |
| Journal | American journal of orthopedics (Belle Mead, N.J.) |
| Volume | 38 |
| Issue number | 8 |
| State | Published - Jan 1 2009 |
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Thromboprophylaxis in orthopedic surgery: how long is long enough?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS